Advertise | About Us | Contact Us

Article - Issue 63

Rethinking Inflammation

- Issue 63

AI and Computational Modeling Approaches for Dose Optimisation During Drug Development

Article - Issue 63

Beyond Perfect Patients

Article - Issue 63

Reinvent Drug Development and Safety with AI

Article - Issue 63

Reimagining Pharmacovigilance

EDITORIAL SECTIONS

Why X-ray Inspection is a Viable Quality Assurance Solution for Pharma Products

Adopting the Power of AI to Drug Development Projects

A tremendous amount of documentation is created throughout the clinical trial lifecycle

Real-world Evidence

Hearing the diagnosis from the doctor that your child has spinal muscular atrophy SMA

Just in Time Manufacturing Creating more sustainable supply chains

Drug development has transformed immeasurably over the past decade Even before the Covid pandemic and the conflict in Ukraine

Challenges and Advantages of Using Artificial Intelligence in Pharma

Many advanced largescale AI initiatives still need to be proved successful in Pharma

Advisory Board

Victor M. Diaz Perez

Brian D Smith

Nigel Cryer FRSC

Quang Bui

Tamara Miller

Imedla Leslie Rillon

Andri Kusandri

Nicoleta Grecu

Alessio Piccoli

Pramod Kashid

Neil J Campbell

mRNA Platforms as Diagnostics and Therapeutics for Human Infertility Treatments

Associate Professor, Department of Biology, Khalifa University
Junaid Kashir is an Associate Professor in the Department of Biology at Khalifa University and has previously chaired multiple researchadministrative committees He has been heavily involved in multiple programs for training graduate clinical embryology students Dr Kashirs research aims to develop therapeuticdiagnostic interventions to treat infertility and understand embryology

Articles

Artificial Intelligence in Oncology

Cancer is the most prevalent cause of death across the globe According to the World Health Organization there is an estimated increase from the anticipated million cases of cancer in It is predicted that more than million

Research Insights

Open For Collaboration: An Academic Platform For Drug Discovery And Development At Scilifelab

Abstract Swedish pharmaceutical industry and research Being a small country with only million inhabitants Sweden has a proud history of successful organic growth of its pharmaceutical industry with companies such as Kabi the first company to license Genentechs recombinant DNA technology later overtaken by Pharmacia subs

Case Studies

Effect Of Cold Spells And Theirmodifiers On Cardiovascular Disease Events: Evidence From A Double Prospective Study

Abstract Cardiovascular disease CVD is the most common cause of death globally remaining a considerable burden both in terms of health and costs As in many countries CVD mortality in the UK exhibits a marked seasonal variation more people die during the winter months DecemberMarch than in other periods of the year and the majority of deaths occur

Techno Trends

89bio Discovered Novel Pegozafermin for Nonalcoholic Steatohepatitis

Pegozafermin stands out as a leading analog of fibroblast growth factor FGF and offers several advantages including robust histological data exceptional tolerability and convenient dosing

White Papers

Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches

In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS

APAC’s Rising Role in Neurodegenerative Disease Research and Development

Simona Lambertini

Simona Lambertini is a senior global clinical research leader with nearly 20 years of experience in international clinical development, research strategy and stakeholder engagement. She has led complex multicountry programs across Europe, North America and the Middle East, collaborating with pharma, biotech and research institutions across high-complexity therapeutic areas.

Advancing Automation and Digitalization in the Industrial Microbiology Workflow

Brad Grobler

Brad is Head of Biomonitoring Strategic Initiatives, which includes development and execution of the Digital strategy in Robotics & Automation, eBusiness, Informatics and the Biomonitoring Ecosystem. Throughout his 10 years at the company, Brad has been engaged in Commercial, Operation and Strategy with regional and global focus.

QSAR - Changing the Landscape of Antidiabetic Drug Discovery

Smriti Sharma

Smriti Sharma Bhatia is an associate professor of chemistry at Miranda House, University of Delhi, India. Her academic and research interests include Computational chemistry and drug design. Currently, her research group is focused on the design of oral drug formulations for Type 2 diabetes mellitus. She is a popular science communicator.

The Value in Decolonising Drug Discovery

Jesse Grey Eagle

Jesse Grey Eagle (Oglala Lakota) is the founder of Indigenous Futures OS and a governance designer for Tribal nations. He works at the nexus of ethical data, AI sovereignty, and long-view institutional systems, advocating for partnership architectures that move beyond extraction.

Dr. Sabah Ul-Hasan

Sabah Ul-Hasan is a Ph.D. scientist with over 15 years of practice in the life sciences. An Indian-Pakistani American based in Albuquerque (New Mexico), Dr. Ul-Hasan centers on ethical data practices that bridge science with community-based knowledge systems.

Redefining Therapeutics

Mads Hald Andersen

Professor Mads Hald Andersen, DMSc, DScTech, PhD, is Director of the National Center for Cancer Immune Therapy, CCIT-DK, at Copenhagen University Hospital Herlev, Denmark. He discovered tumor microenvironment antigens and anti-regulatory T cells and defined their role in immune regulation. He initiated the immune modulatory vaccine concept and has authored more than 250 publications and 25 patents.

INDUSTRY UPDATES

press releasesRead more...

15 UQ researchers to establish new cancer and disease research programs

University of Queensland researchers will accelerate lifechanging health research after securing million from the National Health and Medical Research Council NHMRC

Samsung Bioepis Launches OPUVIZ™ (Aflibercept) 40 mg/mL Pre-filled Syringe Across Europe

Samsung Bioepis Co Ltd today announced the launch of OPUVIZ mgmL solution in prefilled syringe PFS a biosimilar referencing Eylea aflibercept across Europe starting today

Akeso Advances IO2.0 + ADC2.0 Strategy: First Patient Dosed in Phase II Study of TROP2/Nectin-4 Bispecific ADC (AK146D1) Combined with Ivonescimab in Breast Cancer

Akeso Inc HK Akeso or the Company today announced that the first patient has been dosed in a Phase II clinical study AKD evaluating AKD the Companys internally developed TROPNectin

Sobi enters strategic partnership with Innate Pharma to license lacutamab in T-cell lymphoma

Swedish Orphan Biovitrum AB publ Sobi and Innate Pharma SA Euronext Paris IPH Nasdaq IPHA Innate or the Company today announced that they have entered a strategic partnership to enable initiation

Nicox Announces NCX 470 NDA Submission in China by Partner Ocumension

Nicox SA Euronext Growth Paris FR ALCOX an international ophthalmology company today announced that its exclusive licensee in China Ocumension Therapeutics has submitted the New Drug Application

Mediar Therapeutics Enters into a Collaboration and Option Agreement with Ono Pharma to Develop Novel Treatments for Fibro-inflammatory Diseases

Mediar Therapeutics Inc a clinicalstage biotechnology company pioneering firstinclass therapies to halt and reverse fibrosis has entered into a collaboration and option agreement with Ono Pharmaceutical Co